A phase I/II trial of NBTXR3 nanoparticles activated by SBRT in the treatment of liver cancers

Gastrointestinal Cancers Symposium, San Francisco, CA, USA · 2018, Chajon E. et al.


Chajon E.1, Pracht M.1, De Baere T.2, Nguyen F.2, Bronowicki J.-P.3, Vendrely V.4, Baumann A.-S.5,
Croisé-Laurent V.3, Deutsch E.2
1 – Radiation oncology, Centre Eugene – Marquis, Rennes, FR
2 – Radiation oncology, Institut Gustave Roussy, Villejuif, FR
3 – Hepatology and Gastroenterology, Hôpital de Brabois, Vandoeuvre Les Nancy, FR
4 – Radiotherapy, Groupe Hospitalier Sud – Hôpital Haut-Lévêque, Pessac, FR
5 – Radiotherapy, Institut de Cancérologie de Lorraine, Nancy, FR


The physical mode of action of NBTXR3 may represent a breakthrough approach for the local treatment of liver cancers, as it does not engage liver and renal functions, i.e. nanoparticles are not metabolized and not excreted by kidney. A phase I/II trial has been implemented for the treatment of hepatocellular carcinoma and liver metastasis [NCT02721056].

At the 2018 Gastrointestinal Cancers Symposium (also known as ASCO-GI) at San Francisco (CA, USA), Dr. Chajon presented preliminary results on this study.

Overall, the injection of NBTXR3 was safe and well tolerated at these levels. Patients received the planned RT. No DLT occurred. Enrollment is now opened at the 22% level. NBTXR3 shows promising results in terms of safety and antitumor activity and is also currently evaluated in other six clinical studies.

By continuing to use the site, you agree to the use of cookies.En poursuivant votre navigation sur ce site, vous acceptez l’utilisation de cookies. More information.En savoir plus.

The cookie settings on this website are set to “allow cookies” to give you the possibility to switch between languages in a way that this will not interfere with page navigation. If you continue to use this website without changing your cookie settings or you click “Accept” below then you are consenting to this.Par défaut, les paramètres de ce site autorisent les cookies pour vous permettre notamment de naviguer entre les différentes langues disponibles. Nous utilisons des cookies pour vous proposer un site internet facile d'utilisation, sécurisé et fonctionnel. Si vous les autorisez également, cliquez sur « Accepter » ou poursuivez simplement votre navigation.